Hot Investor Mandate 2: Corporate VC Seeks Novel Antibiotics and Alternatives to Antibiotics

3 Nov

A Life Science focused investment fund based in China serves as an internal funding vehicle for a major medical group.  The firm primarily considers investments based in China or has a significant China nexus, for example, the company must have a principal market in China, or R&D/manufacturing/sales in China. The fund prefers to follow and take minority stakes. Investment size varies but typically ranges from US$1-4 million. The fund prefers business models that are marketing/sales oriented (vs. technology oriented). The fund is actively seeking new investment opportunities.

Currently the firm is looking for innovative antibiotics or alternatives to antibiotics in human health, animal health, and agriculture. For the stage of development, the fund seeks products that are able to enter the market within 2 years post investment.

The firm seeks an experienced management team that “has done it before.” The fund will consider US-based companies as long as the China nexus criteria is met. The firm seeks to make minority investment and typically requires China rights.

If you are interested in more information about this investor and other investors tracked by LSN, please email

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

<span>%d</span> bloggers like this: